This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), phar…

Advanced Solid TumorMetastatic Solid TumorEndometrial Cancer+4 more

~Estimated

~$10 – $8,750

MOMA TherapeuticsNCT06974110

Phase 1

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal o…

Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more

~Estimated

Phase 1

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 in Patients With Advanced Solid Tumors With/Without Microsatellite Instability and/or Deficient Mismatch Repair

The goal of this clinical trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in th…

Advanced Solid Tumors CancerMSI-H Cancer

~Estimated

~$10 – $8,750

Nimbus Wadjet, Inc.NCT06898450

~$10 – $8,750

Medicenna Therapeutics, Inc.NCT05086692